Form 4: Harvard Apparatus Regenerative Technology CEO Acquires Shares
SEC Form 4 Filing
He Junli, CEO of Harvard Apparatus Regenerative Technology, reports the acquisition of 1,600 shares of common stock.
Summary
- On June 21, 2024, He Junli, the CEO of Harvard Apparatus Regenerative Technology, Inc. (HRGN), acquired 1,600 shares of common stock at a price of $2.8 per share.
- Following this transaction, He Junli directly owns 254,600 shares of the company's common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by the CEO. While insider buying can be seen as positive, it's a small transaction and doesn't necessarily indicate a strong bullish signal.
Positives
- The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who trade in their company's stock. It provides transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment, as insider buying is often viewed favorably.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of transaction: CEO He Junli acquired 1,600 shares of common stock. |
| 07/02/2024 | Date of report: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.